Smith & Nephew Ends J&J Orthopedics Talks, Cuts 2026 Revenue Outlook
Smith & Nephew confirmed that merger talks with Johnson & Johnson’s orthopedics unit have ended and cut its 2026 revenue outlook.
Related stories
Ridgepost Capital Reports 3Q Revenue of $88.9M
M impact | EARNINGS | Nov 04, 2026, 11:15 AM UTC
Solstice Advanced Materials Expects Q4 Adjusted EPS of $0.57-$0.62
M impact | EARNINGS | Nov 04, 2026, 11:04 AM UTC
Solstice Advanced Materials Posts Q3 Adjusted EPS of $0.80 per Share
Q3 adjusted EPS was $0.80 per share, versus a FactSet estimate of $0.70.
M impact | EARNINGS | Nov 04, 2026, 11:04 AM UTC
Par Pacific Reports Q3 2026 Net Income of $353.3 Million
Par Pacific reported revenue of $3.05 billion and net income attributable to stockholders of $353.3 million, compared with $262.6 million a year earlier. Adjusted EBITDA was $646.0
M impact | EARNINGS | Nov 04, 2026, 11:03 AM UTC
Clear Secure Raises FY 2026 Free Cash Flow Guidance to At Least $490M
Clear Secure raised its FY 2026 free cash flow guidance to at least $490 million, from a prior view of at least $480 million.
M impact | EARNINGS | Nov 04, 2026, 11:03 AM UTC
Maple Leaf Foods Updates FY2026 Adjusted EBITDA Outlook to $520M
Maple Leaf Foods updated its FY2026 adjusted EBITDA outlook to the bottom of its $520 million–$540 million range.
M impact | EARNINGS | Nov 04, 2026, 11:03 AM UTC